Exchange: NASDAQ·Updated 03:24 PM EDT

GRI News

News
all
press releases
GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?
GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened?
The company said that the new data indicate that GRI-0621 may support the regeneration of lung tissue.
Stocktwits
GRI Bio Drug Shows Promising Lung Function Recovery In Patients With Thickened Lungs
GRI Bio shared promising data from a Phase 2a trial for idiopathic pulmonary fibrosis, a chronic lung disease with no known cause.read more...
Benzinga
Barclays lifts Kojamo, I-RES ratings; cuts Grainger on low yield
investing.com

Advertisement|Remove ads.